The Journal of Immunology, Vol 146, Issue 11 3871-3876, Copyright © 1991 by American Association of Immunologists

ARTICLES

Specific amino acid residues in the second hypervariable region of HLA- DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses

JD Reveille, MJ Macleod, K Whittington and FC Arnett
Department of Internal Medicine, University of Texas Health Science Center, Houston 77225.

In order to define the HLA-DR and DQ alleles, as well as the specific DQA1 and DQB1 chain genes involved in the anti-Ro/La autoantibody responses, RFLP analysis and sequence-specific oligonucleotide typing was carried out on 58 Caucasians and 48 American blacks with SLE or Sjogren's syndrome and anti-Ro antibodies. Among both Caucasian and black patients, the highest relative risk for the anti-Ro response (both with and without accompanying anti-La) was conferred by heterozygosity for the DQw2.1 (in linkage disequilibrium with HLA-DR3) and DQw6 (a subtype of DQw1) alleles compared with either 269 normal race-matched controls or 80 anti-Ro negative SLE/Sjogren's syndrome patients. Analysis of individual DQA1 and DQB1 chain alleles revealed that DQA1*0501 and DQB1*0201 were most frequent, followed by DQA1 and DQB1 alleles comprising DQw6. In patients not possessing DQw2.1 and/or DQw6 alleles, HLA-DQB1*0302 and HLA-DQA1*0401 (especially in blacks) were significantly increased. Nucleotide sequence analysis of these associated alleles showed that 100% of patients with anti-Ro had a glutamine residue at position 34 of the outermost domain of the DQA1 chain and/or a leucine at position 26 of the outermost domain of the DQB1 chain. Patients with anti-Ro plus La were more likely to have all four of their DQA1/DQB1 chains containing these amino acid residues than either anti-Ro-negative SLE patients or controls. These data implicate specific amino acid residues on both DQA1 and DQB1 chains located in the floor of the Ag binding cleft of the HLA-DQA1:B1 heterodimer and further suggest a role for "gene dosage" in the anti-Ro (+/- La) autoantibody response.

This article has been cited by other articles:

				A M Bertoli, M Fernandez, G S Alarcon, L M Vila, J D Reveille, and for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability Ann Rheum Dis, January 1, 2007; 66(1): 12 - 17. [Abstract] [Full Text] [PDF]

				N J McHugh, P Owen, B Cox, J Dunphy, and K Welsh MHC class II, tumour necrosis factor {alpha}, and lymphotoxin {alpha} gene haplotype associations with serological subsets of systemic lupus erythematosus Ann Rheum Dis, April 1, 2006; 65(4): 488 - 494. [Abstract] [Full Text] [PDF]

				T. Paisansinsup, U. S. Deshmukh, V. R. Chowdhary, H. S. Luthra, S. M. Fu, and C. S. David HLA Class II Influences the Immune Response and Antibody Diversification to Ro60/Sjogren's Syndrome-A: Heightened Antibody Responses and Epitope Spreading in Mice Expressing HLA-DR molecules J. Immunol., June 1, 2002; 168(11): 5876 - 5884. [Abstract] [Full Text] [PDF]

				A G Tzioufas, R Wassmuth, U G Dafni, A Guialis, H-J Haga, D A Isenberg, R Jonsson, J R Kalden, H Kiener, C Sakarellos, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study Ann Rheum Dis, May 1, 2002; 61(5): 398 - 404. [Abstract] [Full Text] [PDF]

				D. Logar, B. Vidan-Jeras, V. Dolzan, B. Bozic, and T. Kveder The contribution of HLA-DQB1 coding and QBP promoter alleles to anti-Ro alone autoantibody response in systemic lupus erythematosus Rheumatology, March 1, 2002; 41(3): 305 - 311. [Abstract] [Full Text] [PDF]

				M-K Sire, H Julkunen, R Kaaja, and H Ekblad Role of HLA in congenital heart block: susceptibility alleles in children Lupus, January 1, 1999; 8(1): 60 - 67. [Abstract] [PDF]

				J. M Martín-Villa, J. Martínez-Laso, M. A Moreno-Pelayo, M. J Castro-Panete, N. Martínez-Quiles, M. Alvarez, M. D de Juan, J. J Gómez-Reino, and A. Arnaiz-Villena Differential contribution of HLA-DR, DQ, and TAP2 alleles to systemic lupus erythematosus susceptibility in Spanish patients: role of TAP2*01 alleles in Ro autoantibody production Ann Rheum Dis, April 1, 1998; 57(4): 214 - 219. [Abstract] [Full Text]

				T A Podrebarac, D M Boisert, and R Goldstein Clinical correlates, serum autoantibodies and the role of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with SLE Lupus, March 1, 1998; 7(3): 183 - 191. [Abstract] [PDF]

				T. Provost, R. Watson, and E. Simmons-O'Brien Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome Lupus, January 1, 1997; 6(2): 105 - 111. [Abstract] [PDF]

				I. S Gourley, G. Cunnane, B. Bresnihan, O. FitzGerald, and A. L Bell Review : A clinical and serological comparison of familial and non-familial systemic lupus erythematosus in Ireland Lupus, August 1, 1996; 5(4): 288 - 293. [Abstract] [PDF]

				A. Wilson and G. Duff Genetics of tumour necrosis factor in systemic lupus erythematosus Lupus, April 1, 1996; 5(2): 87 - 88. [PDF]

				P.H. Schur Review: Genetics of systemic lupus erythematosus Lupus, December 1, 1995; 4(6): 425 - 437. [PDF]

				W. Chahade, E. Sato, J. Moura JR, L. Costallat, and L. Andrade Occasional Series: Lupus Around the World Systemic lupus erythematosus in Sao Paulo/Brazil: a clinical and laboratory overview Lupus, April 1, 1995; 4(2): 100 - 103. [PDF]